Top

Current Rheumatology Reports

Published in:

01-12-2017 | Systemic Lupus Erythematosus (G Tsokos, Section Editor)

B Cell-Based Treatments in SLE: Past Experience and Current Directions

Authors: Stamatis-Nick C. Liossis, Chrysanthi Staveri

Published in: Current Rheumatology Reports | Issue 12/2017

Abstract

Purpose of Review

B cells have been targeted recently by novel therapeutic approaches in patients with SLE. In this review, we discuss recent data that have emerged on this issue placing special emphasis in studies published during the last 5 years.

Recent Findings

Despite the negative results stemming from double-blind placebo-controlled studies, B cell depletion with rituximab is indeed employed worldwide, particularly in standard treatment refractory lupus, with promising results. In addition, positive experience with the approved agent belimumab is steadily increasing. Both regimens have an acceptable safety profile.

Summary

Identification of B cells as a therapeutic target in SLE has been so far rewarding, since one such treatment, belimumab, has been the only regulatory authority-approved medication in SLE for over half a century. Focusing specifically on autoreactive instead of non-specifically altering/depleting lupus, B cells may lead to more rational treatment modes.

Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest. 1996;98(11):2549–57.CrossRefPubMedPubMedCentral

Rydén-Aulin M, Boumpas D, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med. 2016;3(1):e000163. https://doi.org/10.1136/lupus-2016-000163.CrossRefPubMedPubMedCentral

Witt M, Grunke M, Proft F, Baeuerle M, Aringer M, Burmester G, et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE)—results from a nationwide cohort in Germany (GRAID). Lupus. 2013;22(11):1142–9. https://doi.org/10.1177/0961203313503912.CrossRefPubMed

Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol. 2015;33(4):449–56.PubMed

Hickman RA, Hira-Kazal R, Yee CS, Toescu V, Gordon C. The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. Clin Rheumatol. 2015;34(2):263–71. https://doi.org/10.1007/s10067-014-2839-0.CrossRefPubMed

Bonilla-Abadía F, Coronel Restrepo N, Tobón GJ, Echeverri AF, Muñoz-Buitrón E, Castro AM, et al. Rituximab for remission induction and maintenance in refractory systemic lupus erythematosus. Autoimmune Dis. 2014;2014:731806. https://doi.org/10.1155/2014/731806.PubMedPubMedCentral

Jiang B, Li T, Guo L, Shen H, Ye S, Chen S. Efficacy and safety of rituximab in systemic lupus erythematosus and Sjögren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases. J Clin Rheumatol. 2015;21(5):244–50. https://doi.org/10.1097/RHU.0000000000000273.CrossRefPubMedPubMedCentral

Dias SS, Rodriguez-Garcia V, Nguyen H, et al. Longer duration of B cell depletion is associated with better outcome. Rheumatology (Oxford). 2015;54(10):1876–81. https://doi.org/10.1093/rheumatology/kev036.CrossRef

Tsanian MÉ, Solov'ev SK, Torgashina AV, Aleksandrova EN, Radenska-Lopovok SG, Nikolaeva EV, et al. Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment. Ter Arkh. 2014;86(5):40–9.PubMed

10.

• Aguiar R, Araújo C, Martins-Coelho G, Isenberg D. Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years. Arthritis Care Res (Hoboken). 2017;69(2):257–62. https://doi.org/10.1002/acr.22921. Although retrospective, this study analyzes results from a large number of patients with SLE for a period over a decade.CrossRef

11.

Staveri, Liossis SN. Rituximab for SLE refractory to conventional treatment: results of a cohort evaluating efficacy and long-term outcome. Clin Exp Rheumatol. 2016;34(4):S5.

12.

Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–82. https://doi.org/10.1136/annrheumdis-2012-201940.CrossRefPubMedPubMedCentral

13.

Hahn BH, McMahon M, Wilkinson A, Wallace WD, Daikh DI, FitzGerald J, et al. American College of Rheumatology guidelines for screening, case definition, treatment and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808.CrossRef

14.

Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology (Oxford). 2014;53(9):1570–7. https://doi.org/10.1093/rheumatology/ket462.CrossRef

15.

Tanaka Y, Takeuchi T, Miyasaka N, Sumida T, et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol. 2016;26(1):80–6. https://doi.org/10.3109/14397595.2015.1060665.CrossRefPubMed

16.

• Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280–6. https://doi.org/10.1136/annrheumdis-2012-202844. A highly interesting study addressing the efficacy of RTX + MMF combination in patients with lupus nephritis, without the addition of oral corticosteroids. Despite the lack of a control group and the exclusion of patients with rapidly progressive nephritis, results are promising compared to those reported from other, placebo-controlled randomized trials in patients with LN.CrossRefPubMed

17.

Porter Α, Condon ΜΒ, Doyle AF, Griffith M, Cook T, Cairns T, et al. Prospective long term follow up of the RITUXILUP steroid sparing regimen in lupus nephritis. Nephrol Dial Transplant. 2015;30(suppl_3):iii41. https://doi.org/10.1093/ndt/gfv153.04.CrossRef

18.

Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 2013;22(6):574–82. https://doi.org/10.1177/0961203313483376.CrossRefPubMed

19.

Tambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol. 2015;42(3):541–6. https://doi.org/10.3899/jrheum.140863.CrossRefPubMed

20.

Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2017;4(1):e000182. https://doi.org/10.1136/lupus-2016-000182.CrossRefPubMedPubMedCentral

21.

Lehman TJ, Singh C, Ramanathan A, Alperin R, Adams A, Barinstein L, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J. 2014;2:3. https://doi.org/10.1186/1546-0096-12-3.CrossRef

22.

Ale'ed A, Alsonbul A, Al-Mayouf SM. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus. Rheumatol Int. 2014;34(4):529–33. https://doi.org/10.1007/s00296-013-2896-8.CrossRefPubMed

23.

Watson L, Beresford MW, Maynes C, Pilkington C, Marks SD, Glackin Y, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015;24(1):10–7. https://doi.org/10.1177/0961203314547793.CrossRefPubMed

24.

Fernández-Nebro A, Marenco JL, López-Longo F, Galindo M, Hernández-Cruz BE, Narváez J, et al. The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB). Lupus. 2014;23(10):1014–22. https://doi.org/10.1177/0961203314534909.CrossRefPubMed

25.

Emmi G, Urban ML, Scalera A, Becatti M, Fiorillo C, Silvestri E, et al. Repeated low-dose courses of rituximab in SLE-associated antiphospholipid syndrome: data from a tertiary dedicated centre. Semin Arthritis Rheum. 2017;46(4):e21–3. https://doi.org/10.1016/j.semarthrit.2016.08.002.CrossRefPubMed

26.

Vieregge GB, Harrington TJ, Andrews DM, Carpintero MF, Green DF, Nayer A. Catastrophic antiphospholipid syndrome with severe acute thrombotic microangiopathy and hemorrhagic complications. Case Rep Med. 2013;2013:915309. https://doi.org/10.1155/2013/915309.CrossRefPubMedPubMedCentral

27.

Tse JR, Schwab KE, McMahon M, Simon W. Rituximab: an emerging treatment for recurrent diffuse alveolar hemorrhage in systemic lupus erythematosus. Lupus. 2015;24(7):756–9. https://doi.org/10.1177/0961203314564235.CrossRefPubMed

28.

So MW, Koo BS, Kim YJ, Kim YG, Lee CK, Yoo B. Successful rituximab treatment of refractory hemophagocytic lymphohistiocytosis and autoimmune hemolytic anemia associated with systemic lupus erythematosus. Mod Rheumatol. 2014;24(5):855–7. https://doi.org/10.3109/14397595.2013.874740.CrossRefPubMed

29.

M P, Gabba A, Cauli A, Garau P, Vacca A, Mathieu A. Rituximab treatment for 'rhupus syndrome': clinical and power-Doppler ultrasonographic monitoring of response. A longitudinal pilot study. Lupus. 2013;22(6):624–8. https://doi.org/10.1177/0961203313482741.CrossRef

30.

Haarhaus ML, Svenungsson E, Gunnarsson I. Ofatumumab treatment in lupus nephritis patients. Clin Kidney J. 2016;9(4):552–5. https://doi.org/10.1093/ckj/sfw022.CrossRefPubMedPubMedCentral

31.

Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med. 2014;370(13):1268–70. https://doi.org/10.1056/NEJMc1308488.CrossRefPubMed

32.

EF M, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368–79. https://doi.org/10.1002/art.38037.CrossRef

33.

Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford). 2013;52(7):1313–22. https://doi.org/10.1093/rheumatology/ket129.CrossRef

34.

Wallace DJ, Hobbs K, Clowse ME, Petri M, Strand V, Pike M, et al. Long-term safety and efficacy of epratuzumab in the treatment of moderate-to- severe systemic lupus erythematosus: results from an open-label extension study. Arthritis Care Res (Hoboken). 2016;68(4):534–43. https://doi.org/10.1002/acr.22694.CrossRef

35.

Strand V, Petri M, Kalunian K, Gordon C, Wallace DJ, Hobbs K, et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford). 2014;53(3):502–11. https://doi.org/10.1093/rheumatology/ket378.CrossRef

36.

Tsuru T, Tanaka Y, Kishimoto M, Saito K, Yoshizawa S, Takasaki Y, et al. Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: results from a phase 1/2 randomized study. Mod Rheumatol. 2016;26(1):87–93. https://doi.org/10.3109/14397595.2015.1079292.CrossRefPubMed

37.

Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 2017;69(2):362–75. https://doi.org/10.1002/art.39856.CrossRefPubMedPubMedCentral

38.

Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomized, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73(1):183–90. https://doi.org/10.1136/annrheumdis-2012-202760.CrossRefPubMed

39.

Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis. 2014;73(5):838–44. https://doi.org/10.1136/annrheumdis-2012-202865.CrossRefPubMed

40.

Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144–54. https://doi.org/10.1177/0961203312469259.CrossRefPubMed

41.

van Vollenhoven RF, Petri M, Wallace DJ, Roth DA, Molta CT, Hammer AE, et al. Cumulative corticosteroid dose over fifty-two weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials. Arthritis Rheumatol. 2016;68(9):2184–92. https://doi.org/10.1002/art.39682.CrossRefPubMedPubMedCentral

42.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 2013;65(8):2143–53. https://doi.org/10.1002/art.37995.CrossRefPubMed

43.

Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW, et al. Clinical, laboratory and health-related quality of life correlates of systemic lupus erythematosus responder index response: a post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med. 2014;1(1):e000031. https://doi.org/10.1136/lupus-2014-000031.CrossRefPubMedPubMedCentral

44.

Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 2016;25(7):699–709. https://doi.org/10.1177/0961203315625119.CrossRefPubMedPubMedCentral

45.

Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus. Lupus. 2016;25(14):1587–96.CrossRefPubMedPubMedCentral

46.

Collins CE, Dall’Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3:e000118.CrossRefPubMedPubMedCentral

47.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014;41(2):300–9. https://doi.org/10.3899/jrheum.121368.CrossRefPubMed

48.

Hui-Yuen JS, Reddy A, Taylor J, Li X, Eichenfield AH, Bermudez LM, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42(12):2288–95. https://doi.org/10.3899/jrheum.150470.CrossRefPubMedPubMedCentral

49.

Andreoli L, Reggia R, Pea L, Frassi M, Zanola A, Cartella S, et al. Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients. Isr Med Assoc J. 2014;16(10):651–3.PubMed

50.

Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69(1):115–23. https://doi.org/10.1002/acr.22971.CrossRefPubMed

51.

Schwarting A, Schroeder JO, Alexander T, Schmalzing M, Fiehn C, Specker C, et al. First real-world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: results from the OBSErve Germany Study. Rheumatol Ther. 2016;3(2):271–90.CrossRefPubMedPubMedCentral

52.

Scheinberg M, de Melo FF, Bueno AN, Costa CM, de Azevedo Bahr ML, Reis ER. Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients. Clin Rheumatol. 2016;35(7):1719–23. https://doi.org/10.1007/s10067-016-3268-z.CrossRefPubMed

53.

Sthoeger Z, Lorber M, Tal Y, Toubi E, Amital H, Kivity S, et al. Anti-BLyS treatment of 36 Israeli systemic lupus erythematosus patients. Isr Med Assoc J. 2017;19(1):44–8.PubMed

54.

Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, et al. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study. Rheumatol Int. 2017;37(6):865–73. https://doi.org/10.1007/s00296-017-3682-9.CrossRefPubMedPubMedCentral

55.

Yapa SW, Roth D, Gordon D, Struemper H. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus phase 3 program. Lupus. 2016;25(13):1448–55. https://doi.org/10.1177/0961203316642309.CrossRefPubMedPubMedCentral

56.

Lee YH, Song GG. Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials. Lupus. 2017;1:961203317713143. https://doi.org/10.1177/0961203317713143.

57.

Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(5):1016–27. https://doi.org/10.1002/art.40049.CrossRefPubMedPubMedCentral

58.

Vashisht P, Borghoff K, O'Dell JR, Hearth-Holmes M. Belimumab for the treatment of recalcitrant cutaneous lupus. Lupus. 2017;26(8):857–64. https://doi.org/10.1177/0961203316682097.CrossRefPubMed

59.

Flieber EE, Korsten P, Koziolek MJ, Niewold TB, Patchan D, Muller GA, et al. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman. Lupus. 2013;22:1523–5.CrossRef

60.

De Sceerder M-A, Boey O, Mahieu E, Vanuytsel J, Bogaert A-M. Case report: successful treatment of membranous lupus nephritis with belimumab in an African female immigrant. Clin Rheumatol. 2016;35:1649–53.CrossRef

61.

Sjӧwall C, Cӧster L. Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity. Scand J Rheumatol. 2014;43(5):428–30.CrossRef

62.

• Staveri C, Karokis D, Liossis SNC. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab. Semin Arthritis Rheum. 2017;46(6):788–90. https://doi.org/10.1016/j.semarthrit.2016.09.006. Although limited to 2 patients, this report identifies 2 patients developing LN shortly after belimumab initiation. Nephritis underwent a complete response following belimumab withdrawal.CrossRefPubMed

63.

Gonzalez-Echavarri C, Uqarte A, Ruiz-Irastorza G. Rituximab-refractory lupus nephritis successfully treated with belimumab. Clin Exp Rheumatol. 2016;34(2):355–6.PubMed

64.

Simonetta, et al. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine. 2016; https://doi.org/10.1016/j.jbspin.2016.01.008.

65.

Kraaij T, Huizinga TW, Rabelink TJ, Teng YK. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology (Oxford). 2014;53(11):2122–4.CrossRef

66.

Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman MH, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015;17:215. https://doi.org/10.1186/s13075-015-0741-z.CrossRefPubMedPubMedCentral

67.

Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015;74(9):1667–75. https://doi.org/10.1136/annrheumdis-2013-205144.CrossRefPubMed

68.

Petri MA, Martin RS, Scheinberg MA, Furie RA. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the phase 2 clinical trial with blisibimod. Lupus. 2017;26(1):27–37.CrossRefPubMed

69.

Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):323–31. https://doi.org/10.1136/annrheumdis-2015-207653.CrossRefPubMed

70.

Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):332–40. https://doi.org/10.1136/annrheumdis-2015-207654.CrossRefPubMed

71.

Tanaka Y, Takeuchi T, Akashi N, Takita Y, Kovacs B, Kariyasu S. Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: subgroup analyses of the ILLUMINATE-1 study. Mod Rheumatol. 2017;27(2):284–91. https://doi.org/10.1080/14397595.2016.1206260.CrossRefPubMed

72.

Rovin BH, Dooley MA, Radhakrishnan J, Ginzler EM, Forrester TD, Anderson PW. The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials. Lupus. 2016;25(14):1597–601.CrossRefPubMed

73.

Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006–15. https://doi.org/10.1136/annrheumdis-2013-205067. Erratum in: Ann Rheum Dis. 2016; 75(5):946

74.

Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D. Post hoc analysis of the phase II/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL. Arthritis Rheumatol. 2017;69(1):122–30. https://doi.org/10.1002/art.39809.CrossRefPubMed

Title: B Cell-Based Treatments in SLE: Past Experience and Current Directions
Authors: Stamatis-Nick C. Liossis
Chrysanthi Staveri
Publication date: 01-12-2017
Publisher: Springer US
Published in: Current Rheumatology Reports / Issue 12/2017
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-017-0707-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 12/2017

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts

Renal Macrophages and Dendritic Cells in SLE Nephritis

Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment

Tendon Pathology in Hypercholesterolemia and Familial Hypercholesterolemia

Clinical Outcome and Long-term Remission in JIA

Can positive affect attenuate (persistent) pain? State of the art and clinical implications

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials